BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wawruszak A, Luszczki J, Czerwonka A, Okon E, Stepulak A. Assessment of Pharmacological Interactions between SIRT2 Inhibitor AGK2 and Paclitaxel in Different Molecular Subtypes of Breast Cancer Cells. Cells 2022;11:1211. [PMID: 35406775 DOI: 10.3390/cells11071211] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Djokovic N, Rahnasto-Rilla M, Lougiakis N, Lahtela-Kakkonen M, Nikolic K. SIRT2i_Predictor: A Machine Learning-Based Tool to Facilitate the Discovery of Novel SIRT2 Inhibitors. Pharmaceuticals (Basel) 2023;16. [PMID: 36678624 DOI: 10.3390/ph16010127] [Reference Citation Analysis]
2 Marzęda P, Wróblewska-Łuczka P, Florek-Łuszczki M, Drozd M, Góralczyk A, Łuszczki JJ. Comparison of the Anticancer Effects of Arvanil and Olvanil When Combined with Cisplatin and Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis. Int J Mol Sci 2022;23. [PMID: 36430670 DOI: 10.3390/ijms232214192] [Reference Citation Analysis]
3 Wawruszak A, Okon E, Telejko I, Czerwonka A, Luszczki J. Additive pharmacological interaction between sirtuin inhibitor cambinol and paclitaxel in MCF7 luminal and MDA-MB-231 triple-negative breast cancer cells. Pharmacol Rep 2022. [PMID: 35900723 DOI: 10.1007/s43440-022-00393-w] [Reference Citation Analysis]
4 Wawruszak A, Luszczki J, Okon E, Czerwonka A, Stepulak A. Antagonistic Pharmacological Interaction between Sirtuin Inhibitor Cambinol and Paclitaxel in Triple-Negative Breast Cancer Cell Lines: An Isobolographic Analysis. Int J Mol Sci 2022;23:6458. [PMID: 35742901 DOI: 10.3390/ijms23126458] [Reference Citation Analysis]